LIALDA demonstrates prolonged release of mesalamine in an in vitro study using a simulated colon

Philadelphia, PA October 17, 2007 According to a study using a dynamic in vitro gastrointestinal tract system, Shire plc's (LSE: SHP, NASDAQ: SHPGY, TSX: SHQ) ulcerative colitis drug LIALDA (mesalamine) demonstrated a delivery system where the majority of the drugs active ingredient, 5-aminosali...

Shire Expands Gastrointestinal Patient Assistance Program for Uninsured or Unemployed Americans

...alda if you are allergic to salicylates (including mesalamine or aspirin) or to any of the ingredients of Lialda...stomach blockage or are allergic to sulfasalazine. mesalamine has been associated with a syndrome that may be di...k to your doctor immediately. Some patients taking mesalamine have reported heart-related hypersensitivity react...

Long-Term Safety Data on Lialda(TM) (mesalamine) for Patients With Ulcerative Colitis Published in Leading GI Journal

...loric stenosis or those allergic to sulfasalazine. mesalamine has been associated with an acute intolerance synd...(three percent of patients in clinical trials with mesalamine or sulfasalazine) that may be difficult to disting...orts of renal impairment have been associated with mesalamine medications. In patients with renal impairment, ca...

Alaven Pharmaceutical Introduces Kit for UC Patients

...des in certain susceptible people. The overall prevalence of sulfite sensitivity in the general population is unknown but probably low. Precautions: mesalamine has been implicated in the production of an acute intolerance syndrome characterized by cramping, acute abdominal pain and bloody diarrhea, sometimes ...

Shire Launches Patient Education Forums on Better Managing the Challenges of Ulcerative Colitis

...ulcerative colitis), with a tablet core containing mesalamine with hydrophilic and lipophilic components. Shir...loric stenosis or those allergic to sulfasalazine. mesalamine has been associated with an acute intolerance synd....5 percent), and rash (1.0 percent). As with other mesalamine products, serious adverse events may occur. PENTAS...

Nationwide Survey Reveals Differing Physician and Patient Perceptions Regarding Impact of Ulcerative Colitis on Patients' Lives

...ulcerative colitis), with a tablet core containing mesalamine with hydrophilic and lipophilic excipients. Shir...loric stenosis or those allergic to sulfasalazine. mesalamine has been associated with an acute intolerance synd....5 percent), and rash (1.0 percent). As with other mesalamine products, serious adverse events may occur. PENTAS...

Further Upgrade to 2007 Financial Guidance Based on Strong Revenue Growth; VYVANSE Demand on Track

...ed to the same period in 2006 primarily due to a 4% increase in the US oral mesalamine prescription market, offset by a small decrease in PENTASA's average market...of LIALDA in March 2007, PENTASA and LIALDA's combined share of the US oral mesalamine prescription market had grown to 23% by September 30, 2007, up from 18% at ...

Mesalamine linked to cancer protection for high risk inflammatory bowel disease patients

...15, 2007, Philadelphia, PA Researchers found that mesalamine use among patients with inflammatory bowel disease...ine. This finding suggests an association between mesalamine use and reduced risk of colorectal cancer, accordi...ich revealed that at doses greater than 5068 grams mesalamine use in patients with IBD was associated with an 89...

Good bacteria to rescue of colitis patients

..., Fedorak said. The VSL#3 can be considered an important potential treatment for those patients who don't respond to conventional therapy such as mesalamine or 5ASA, he said. (IANS) ...

mesalamine in Medical Technology

Shire Presented Results of a New Database Analysis on Lialda(R) (Mesalamine) and Other 5-ASAs for Ulcerative Colitis at Digestive Disease Week

... many, and how often, patients are refilling their mesalamine prescriptions." The database analysis evaluat...loric stenosis or those allergic to sulfasalazine. mesalamine has been associated with an acute intolerance syndrome (3% of patients in clinical trials with mesalamine or sulfasalazine) that may be difficult to disting...

Safety and Efficacy Results Presented From Largest Prospective Controlled Clinical Study of Ulcerative Colitis

...e colitis (UC) receiving an investigational 800 mg mesalamine tablet dosed at 4.8 g/day under development by Pro...tigational tablet and dose were compared to 400 mg mesalamine tablets dosed at 2.4 g/day. Additionally, patien... Center. "In this study the investigational 800 mg mesalamine tablet dosed at 4.8 g/day was well-tolerated and h...

Analysis of Ulcerative Colitis (UC) Time to Symptom Resolution Data from Pivotal Study of LIALDA(TM) (mesalamine) Presented at DDW

...loric stenosis or those allergic to sulfasalazine. mesalamine has been associated with an acute intolerance synd...orts of renal impairment have been associated with mesalamine medications. In patients with renal impairment, ca...ulcerative colitis), with a tablet core containing mesalamine with hydrophilic and lipophilic components. Shir...

Study Data Show Asacol(R) (Mesalamine) is Effective in Treating All Extents of Ulcerative Colitis Including Isolated Proctitis

...may involve heredity, infection or the immune system. About Asacol(R) (mesalamine) Delayed-Release Tablets 400 mg Asacol is a delayed-release oral mesalamine tablet indicated for the treatment of mildly to moderately active UC (the indicated dosage is two 400 mg tablets to be taken three times a day for six...

New Analysis of Study Data Shows That Asacol(R) (Mesalamine) Delivers Rapid Symptom Relief for Ulcerative Colitis Patients

...t may involve heredity, infection or the immune system. About Asacol(R) (mesalamine) Delayed-Release Tablets 400 mg Asacol is a delayed-release oral mesalamine tablet indicated for the treatment of mildly to moderately active UC (the indicated dosage is two 400 mg tablets tid for 6 weeks) and for the maintena...

New Analyses of Long-Term LIALDA(TM) (mesalamine) Data Presented at ACG

...ulcerative colitis), with a tablet core containing mesalamine with hydrophilic and lipophilic excipients. Shire...loric stenosis or those allergic to sulfasalazine. mesalamine has been associated with an acute intolerance synd...(three percent of patients in clinical trials with mesalamine or sulfasalazine) that may be difficult to disting...

Ulcerative Colitis (UC) Sufferers Find UC Quite Disruptive to Many Aspects of Daily Life

...e of the inflammation in ulcerative colitis), with a tablet core containing mesalamine with hydrophilic and lipophilic excipients. LIALDA has only been studied ...e not been established. You should not take Lialda if you are allergic to mesalamine or other salicylates (such as aspirin), or to any of the other ingredients ...

Analysis of Ulcerative Colitis (UC) Remission Rates from Long-term Safety Study of Lialda (mesalamine) Presented at DDW

...e UC, LIALDA is the first and only oral once-daily mesalamine on the market. Safety and effectiveness have been ...ulcerative colitis), with a tablet core containing mesalamine with hydrophilic and lipophilic excipients. Shir...loric stenosis or those allergic to sulfasalazine. mesalamine has been associated with an acute intolerance synd...

Separate Sets of Research Show Treatment Improved Quality of Life in as Early as Three Weeks; Patient Adherence to Medication is Multifactorial

...s Three Weeks The abstract, "Delayed-release mesalamine significantly improved quality of life (QoL) in ...ients treated for six weeks with delayed-release mesalamine Asacol 2.4g (marketed 400mg tablet) daily or 4.8g daily (investigational 800mg mesalamine tablet). Data from two multicenter, randomized, ...

Salix Pharmaceuticals Announces Positive Top Line Results of Balsalazide Tablets Registration Study

...d Proctocort(R) Suppositories (Hydrocortisone Acetate Rectal Suppositories, 30 mg). SANVAR(R) IR (vapreotide acetate), balsalazide tablets, granulated mesalamine and XIFAXAN(R) for additional indications are under development. For full prescribing information on Salix products, please visit www.salix.com. S...

mesalamine in Biological Technology

Shire and TAP Agree to Co-promote LIALDA(TM) (mesalamine), the First Oral Once-Daily Mesalamine For Patients With Active, Mild to Moderate Ulcerative Colitis

Forms One of the Largest Sales Teams Promoting a 5-ASA Medicine BASINGSTOKE, England and PHILADELPHIA, March 26 /PRNewswire-FirstCall/ -- Shire plc (LSE: SHP, NASDAQ: SHPGY), the global specialty biopharmaceutical company, announced today a co-promotion agreement with TAP Pharmaceutical Pr...

Shire plc: Core Portfolio of Products Delivers 20% Sales Growth

... three months to June 30, 2009 of $4.9 million (2008: $nil). US oral mesalamine market share Shire's average market share of the US oral mesalamine market rose to 31.8% for the three months to June 30, 2009 (2008: 27.6%). ...

Shire begins the year with a strong performance

...YTRANA only declined by 2% primarily due to price increases. US oral mesalamine market share Driven by the growth of LIALDA since its launch in March 2007, Shire's average market share of the US oral mesalamine market rose to 31.1% for the three months to March 31, 2009 (2008: 26.1%). ...

Shire Delivers Excellent Growth for the Year, With the new Product Portfolio Achieving Sales of $1 Billion

...tion in the production of DAYTRANA. US oral mesalamine market share Shire's average annual market share of the US oral mesalamine market rose to 28.4% for the year to December 31, ...7% in 2008, offset by a 2% increase in the US oral mesalamine prescription market. Sales of PENTASA for t...

Shire's New Product Portfolio Delivers Strong Quarterly Performance

...n may take additional corrective action. US oral mesalamine market share Shire's average quarterly market share of the US oral mesalamine market rose to 29.3% in the three months to Septem...ince its launch in March 2007. The overall US oral mesalamine market grew by 2.4% in the same period. LIALDA/M...

Shire Delivers Strong Quarter: Driven by $243m of New Product Sales (+164% YOY Growth). Revenue Guidance Upgrade.

...e production of DAYTRANA is anticipated. US oral mesalamine market share Shire's average quarterly market share of the US oral mesalamine market rose to 27.6% in the three months to June 3...ive colitis Shire launched LIALDA in the US oral mesalamine market in March 2007, and during the three months ...

Following a Good Start to the Year Shire Reaffirms Full Year 2008 Financial Guidance

...l 22,000 doctors. - Shire's share of the US oral mesalamine market from LIALDA and PENTASA combined increased ...ive colitis Shire launched LIALDA in the US oral mesalamine prescription market in March 2007, and during the ...0% in 2008, offset by a 3% increase in the US oral mesalamine market. Since the launch of LIALDA in March 2007...

Shire plc: IFRS Results for the Year Ending December 31, 2007

...2006 primarily due to a 4% increase in the US oral mesalamine prescription market, offset by a 0.1% decrease in ...ive colitis Shire launched LIALDA in the US oral mesalamine market in March 2007, and by December 31, 2007 LIA...PENTASA and LIALDA's combined share of the US oral mesalamine prescription market had grown to 24.9% as at Decem...

Shire plc: Excellent Performance Across All Areas of the Business and Accelerating New Product Sales Drive Revenue Growth of 36%

... - LIALDA, the only once-daily oral formulation of mesalamine was approved by the FDA in January 2007 and launch...in March 2007, acquiring 8.0% share of the US oral mesalamine market at December 31, 2007. Sales for 2007 were $50.5 million. - Shire's share of the US oral mesalamine market from LIALDA and PENTASA(R) combined was 26....

IFRS Information - First Half of 2007

.... PENTASA PENTASA's average share of the US oral mesalamine prescription market remained stable at 17% for the...he GI sales force and a 4% increase in the US oral mesalamine prescription market. Sales of PENTASA for the six...ALDA LIALDA's average market share of the US oral mesalamine market from the launch of LIALDA in March 2007 thr...